135473-17-5

Basic information

• Product Name: N⁶-benzoyl-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
• Synonyms: N⁶-benzoyl-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine
• CAS NO: 135473-17-5
• Molecular Weight: 581.56
• Mol File: 135473-17-5.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: N⁶-benzoyl-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine(CAS DataBase Reference)
• NIST Chemistry Reference: N⁶-benzoyl-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine(135473-17-5)
• EPA Substance Registry System: N⁶-benzoyl-9-(3,5-di-O-benzoyl-2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine(135473-17-5)

Safety Data

• Hazardous Substances Data: 135473-17-5(Hazardous Substances Data)

Upstream product

• 97614-43-2 1,3,5-tri-O-benzoyl-2-deoxy-2-fluoro-α-D-arabinofuranose 
• 97614-44-3 2-deoxy-2-fluoro-3,5-di-O-benzoyl-α-D-arabinofuranosyl bromide 
• 4005-49-6 N-benzoyladenine 
• 62374-24-7 (2R,3S,4R,5R)-5-(6-amino-9H-purin-9-yl)-2-((benzoyloxy)methyl)-4-hydroxytetrahydrofuran-3-yl benzoate 
• 98-88-4 benzoyl chloride 
• 58-61-7 adenosine 

Downstream Products

• 144924-99-2 N-(9-((2R,3S,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-9H-purin-6-yl)benzamide 
• 1412911-81-9 C₂₃H₂₈FN₅O₅Si 
• 1412911-85-3 C₁₇H₁₄FN₅O₅ 
• 1048373-98-3 C₂₃H₃₀FN₅O₄Si 
• 1412911-80-8 C₂₉H₄₄FN₅O₄Si₂ 
• 20187-82-0 9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine 

Relevant articles and documents

Synthesis of Rovafovir Etalafenamide (Part IV): Evolution of the Synthetic Process to the Fluorinated Nucleoside Fragment

Fluorinated nucleoside 1 is a key starting material in the synthesis of rovafovir etalafenamide (2), a novel nucleotide reverse transcriptase inhibitor under development at Gilead Sciences for the treatment of HIV. While an initial manufacturing route enabled the production of 1 to support clinical development, alternative approaches were explored to further enhance manufacturing effectiveness, improve processing time, reduce cost, and minimize the environmental impact. Toward this end, two new routes were developed to a key synthetic intermediate, which was converted to 1 using a new protecting group strategy. The new chemistry led to improvements in the manufacturing process while reducing the overall process mass intensity (PMI).

ANTIVIRAL DRUG

PROBLEM TO BE SOLVED: To provide a nucleic acid analog having excellent antiviral activity (particularly anti-hepatitis B virus activity). SOLUTION: The invention provides a compound represented by the formula (I) in the figure, where each symbol is as defined in the specification, or a salt thereof. SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

PROCESSES AND INTERMEDIATES FOR PREPARING ANTI-HIV AGENTS

The invention provides synthetic processes and synthetic intermediates that can be used to prepare compounds having useful anti-HIV properties.